» Articles » PMID: 29236297

MRI Change Metrics of Facioscapulohumeral Muscular Dystrophy: Stir and T1

Overview
Journal Muscle Nerve
Date 2017 Dec 14
PMID 29236297
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: MRI evaluation in facioscapulohumeral muscular dystrophy (FSHD) demonstrates fatty replacement and inflammation/edema in muscle. Our previous work demonstrated short T1 inversion recovery (STIR)-hyperintense (STIR+) signal in muscle 2 years before fatty replacement. We evaluated leg muscle STIR changes and fatty replacement within 14 months.

Methods: FSHD subjects received 2 MRI scans of thigh and calf over a 6.9- to 13.8-month interval. Quality of life measures were collected. One Radiologist rated muscle changes on a semi-quantitative scale.

Results: Fifteen subjects completed longitudinal imaging. Four STIR + muscles and 3 STIR-normal (STIR-) muscles were rated as progressing to fatty tissue over the study period.

Discussion: STIR + muscles with confluent regions of fat at baseline increased more in fat, while STIR- muscles had increases in septal-fat over the study period. These changes may reflect two phases of FSHD, demonstrating MRI sensitivity is weighted toward gross pathological phases of the disease. Muscle Nerve 57: 905-912, 2018.

Citing Articles

Facioscapulohumeral Dystrophy: Molecular Basis and Therapeutic Opportunities.

Arends T, Hamm D, van der Maarel S, Tapscott S Cold Spring Harb Perspect Biol. 2024; .

PMID: 39009417 PMC: 11733064. DOI: 10.1101/cshperspect.a041492.


AI driven analysis of MRI to measure health and disease progression in FSHD.

Riem L, DuCharme O, Cousins M, Feng X, Kenney A, Morris J Sci Rep. 2024; 14(1):15462.

PMID: 38965267 PMC: 11224366. DOI: 10.1038/s41598-024-65802-x.


Regional and bilateral MRI and gene signatures in facioscapulohumeral dystrophy: implications for clinical trial design and mechanisms of disease progression.

Wong C, Friedman S, Snider L, Bennett S, Jones T, Jones P Hum Mol Genet. 2024; 33(8):698-708.

PMID: 38268317 PMC: 11000661. DOI: 10.1093/hmg/ddae007.


Lean tissue mass measurements by dual-energy X-ray absorptiometry and associations with strength and functional outcome measures in facioscapulohumeral muscular dystrophy.

Wang L, Leung D, Wagner K, Lowry S, McDermott M, Eichinger K Neuromuscul Disord. 2023; 33(9):63-68.

PMID: 37400350 PMC: 10527411. DOI: 10.1016/j.nmd.2023.06.008.


Five-year follow-up study on quantitative muscle magnetic resonance imaging in facioscapulohumeral muscular dystrophy: The link to clinical outcome.

Vincenten S, Mul K, van As D, Jansen J, Heskamp L, Heerschap A J Cachexia Sarcopenia Muscle. 2023; 14(4):1695-1706.

PMID: 37218549 PMC: 10401523. DOI: 10.1002/jcsm.13250.